Author of

• 12701

  +

  P3.12 - Poster Session 3 - NSCLC Early Stage (ID 206)

  • Event: WCLC 2013
  • Type: Poster Session
  • Track: Medical Oncology
  • Presentations: 1
  • Moderators:
  • Coordinates: 10/30/2013, 09:30 - 16:30, Exhibit Hall, Ground Level

  • 12715

    +

    P3.12-014 - Prognostic impact of lymphovascular invasion according to the tumor size in patients with pN0 non-small cell lung cancer (ID 2527)

    09:30 - 09:30  |  Author(s): A. Takahagi
    • Abstract

    Background
    Lymphovascular invasion (LVI) has been reported to be an unfavorable prognostic factor in patients with non-small cell lung cancer (NSCLC). We investigated the prognostic impact of LVI according to the tumor size in patients with pN0 NSCLC to elucidate the candidates for adjuvant chemotherapy.

    Methods
    Records of a total of 274 patients with pN0 NSCLC who underwent lobectomy with hilar and mediastinal lymph-node dissection were reviewed. Patients were divided into 3 groups according to the tumor diameter; group A: smaller than 20 mm, group B: 21 to 30 mm, and group C: greater than 31 mm. The comparison between the groups (A, B, and C) and LVI status (positive/negative) was analyzed by chi-square test. Kaplan-Meier analyses and log-rank tests with 95 % confidence intervals were employed to evaluate the impact of LVI on overall survival (OS) and relapse-free survival (RFS) in each group. Cox proportional hazards models were applied to assess the independent risk factors.

    Results
    Group A, B, and C consisted of 99, 86, and 89 patients, respectively. The frequency of positive LVI was increased in larger tumors (group A: 19.2%, group B: 25.6%, and group C: 36.0%; P = 0.033). In both group A and B patients, positive LVI was a significant risk factor for poor prognosis of OS and RFS in univariate analysis. In multivariate analysis, positive LVI was an independent risk factor for OS in both group A and B patients (hazard ratio = 10.6 and 10.5, P = 0.005 and 0.006, respectively) and for RFS in group A patients (hazard ratio = 14.7, P = 0.001)．LVI status was not shown to be a prognostic factor for OS or RFS in group C patients.

    Conclusion
    The impact of positive LVI on prognosis was more significant in the smaller tumors, although the frequency of LVI was higher in the larger tumors. Adjuvant chemotherapy for patients with pN0 small-sized NSCLC and positive LVI should be considered.